Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Area of Science:

• Gastroenterology
• Immunology
• Clinical Trials

Background:

• Biologic therapies are mainstays in ulcerative colitis (UC) treatment.
• Head-to-head trials comparing these biologics in inflammatory bowel disease (IBD) are limited.

Purpose of the Study:

• To compare the efficacy of vedolizumab versus adalimumab in patients with moderately to severely active UC.
• To determine if vedolizumab is superior to adalimumab in achieving clinical remission at 52 weeks.

Main Methods:

• A phase 3b, double-blind, double-dummy, randomized controlled trial (VARSITY) involving 769 patients.
• Patients received either vedolizumab infusions or adalimumab injections for 52 weeks.
• Primary outcome was clinical remission defined by the Mayo score; secondary outcomes included endoscopic improvement and corticosteroid-free remission.

Main Results:

• Vedolizumab showed higher rates of clinical remission (31.3% vs. 22.5%) and endoscopic improvement (39.7% vs. 27.7%) compared to adalimumab at week 52.
• No significant difference was found in corticosteroid-free remission (12.6% vs. 21.8%).
• Infection rates were lower with vedolizumab (23.4 events/100 patient-years) versus adalimumab (34.6 events/100 patient-years).

Conclusions:

• Vedolizumab is superior to adalimumab in achieving clinical remission and endoscopic improvement in moderate to severe UC.
• While both therapies are effective, vedolizumab offers better outcomes for these specific endpoints.
• The study provides valuable head-to-head data for optimizing biologic selection in UC management.